治疗子宫内膜异位症的激素药物

IF 4 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Tommaso Capezzuoli, Margherita Rossi, Francesco La Torre, Silvia Vannuccini, Felice Petraglia
{"title":"治疗子宫内膜异位症的激素药物","authors":"Tommaso Capezzuoli,&nbsp;Margherita Rossi,&nbsp;Francesco La Torre,&nbsp;Silvia Vannuccini,&nbsp;Felice Petraglia","doi":"10.1016/j.coph.2022.102311","DOIUrl":null,"url":null,"abstract":"<div><p>In the past, the primary approach for the treatment of endometriosis was represented by surgery; however, after the introduction of non-invasive diagnosis of endometriosis with the development of imaging technologies, medical treatment became the preferred approach, particularly in young patients. Hormonal drugs, by blocking menstruation, are the most effective for the treatment of endometriosis-related pain, independently of phenotype (ovarian, deep, or superficial endometriosis).</p><p>Gonadotropin-releasing hormone analogs and oral antagonists act on hypothalamus-pituitary-ovary axis inducing iatrogenic menopause, thus reducing dysmenorrhea<span> and all pain symptoms. The side effects, such as hot flushes and bone loss, may be reduced by an add-back therapy. However, the cost in terms of women's health remains high in view of a long-term treatment.</span></p><p><span>Progestins are considered the first-line treatment, highly effective, and with reduced side effects. In addition to the well-known and largely used </span>Norethisterone acetate<span><span> and Medroxyprogesterone acetate, recently </span>Dienogest<span> has become one of the most used drugs in all endometriosis phenotypes for long-term treatment. Besides, Intrauterine levornogestrel or subcutaneous etonogestrel are valid alternative for long-term treatment.</span></span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102311"},"PeriodicalIF":4.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":"{\"title\":\"Hormonal drugs for the treatment of endometriosis\",\"authors\":\"Tommaso Capezzuoli,&nbsp;Margherita Rossi,&nbsp;Francesco La Torre,&nbsp;Silvia Vannuccini,&nbsp;Felice Petraglia\",\"doi\":\"10.1016/j.coph.2022.102311\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>In the past, the primary approach for the treatment of endometriosis was represented by surgery; however, after the introduction of non-invasive diagnosis of endometriosis with the development of imaging technologies, medical treatment became the preferred approach, particularly in young patients. Hormonal drugs, by blocking menstruation, are the most effective for the treatment of endometriosis-related pain, independently of phenotype (ovarian, deep, or superficial endometriosis).</p><p>Gonadotropin-releasing hormone analogs and oral antagonists act on hypothalamus-pituitary-ovary axis inducing iatrogenic menopause, thus reducing dysmenorrhea<span> and all pain symptoms. The side effects, such as hot flushes and bone loss, may be reduced by an add-back therapy. However, the cost in terms of women's health remains high in view of a long-term treatment.</span></p><p><span>Progestins are considered the first-line treatment, highly effective, and with reduced side effects. In addition to the well-known and largely used </span>Norethisterone acetate<span><span> and Medroxyprogesterone acetate, recently </span>Dienogest<span> has become one of the most used drugs in all endometriosis phenotypes for long-term treatment. Besides, Intrauterine levornogestrel or subcutaneous etonogestrel are valid alternative for long-term treatment.</span></span></p></div>\",\"PeriodicalId\":50603,\"journal\":{\"name\":\"Current Opinion in Pharmacology\",\"volume\":\"67 \",\"pages\":\"Article 102311\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1471489222001382\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1471489222001382","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 7

摘要

过去,治疗子宫内膜异位症的主要方法是手术;然而,随着影像技术的发展,子宫内膜异位症的无创诊断被引入后,药物治疗成为首选方法,特别是在年轻患者中。激素药物,通过阻断月经,是最有效的治疗子宫内膜异位症相关的疼痛,独立于表型(卵巢,深部或浅表性子宫内膜异位症)。促性腺激素释放激素类似物和口服拮抗剂作用于下丘脑-垂体-卵巢轴,诱导医疗源性绝经,从而减轻痛经和所有疼痛症状。副作用,如潮热和骨质流失,可以通过加回治疗来减少。然而,考虑到长期治疗,妇女健康方面的费用仍然很高。孕激素被认为是第一线治疗,非常有效,而且副作用少。除了众所周知且大量使用的醋酸去甲睾酮和醋酸甲孕酮外,近年来Dienogest已成为所有子宫内膜异位症表型中最常用的长期治疗药物之一。此外,子宫内注射左旋孕酮或皮下注射炔诺孕酮是长期治疗的有效选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Hormonal drugs for the treatment of endometriosis

In the past, the primary approach for the treatment of endometriosis was represented by surgery; however, after the introduction of non-invasive diagnosis of endometriosis with the development of imaging technologies, medical treatment became the preferred approach, particularly in young patients. Hormonal drugs, by blocking menstruation, are the most effective for the treatment of endometriosis-related pain, independently of phenotype (ovarian, deep, or superficial endometriosis).

Gonadotropin-releasing hormone analogs and oral antagonists act on hypothalamus-pituitary-ovary axis inducing iatrogenic menopause, thus reducing dysmenorrhea and all pain symptoms. The side effects, such as hot flushes and bone loss, may be reduced by an add-back therapy. However, the cost in terms of women's health remains high in view of a long-term treatment.

Progestins are considered the first-line treatment, highly effective, and with reduced side effects. In addition to the well-known and largely used Norethisterone acetate and Medroxyprogesterone acetate, recently Dienogest has become one of the most used drugs in all endometriosis phenotypes for long-term treatment. Besides, Intrauterine levornogestrel or subcutaneous etonogestrel are valid alternative for long-term treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.80
自引率
2.50%
发文量
131
审稿时长
4-8 weeks
期刊介绍: Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信